Skip to main content
. 2024 May 7;15(3):432–453. doi: 10.14740/wjon1845

Table 15. Demographics and Clinical Characteristics for Gastric Cancer by Histology.

Gastric All Adenocarcinoma Squamous Adenosquamous P value
N (%) 163,791 (100.0) 103,143 (63.0) 1,306 (0.8) 479 (0.3)
Age (years) (%)
  0 - 14 45 (< 1) 3 (< 1) 0 (0.0) 0 (0.0) < 0.001
  15 - 29 1,149 (0.7) 493 (0.5) 4 (0.3) 2 (0.4)
  30 - 49 16,632 (10.2) 8,103 (7.9) 76 (5.8) 39 (8.1)
  50 - 69 66,842 (40.8) 41,002 (39.8) 632 (48.4) 257 (53.7)
  70 - 89 79,123 (48.3) 53,542 (51.9) 594 (45.5) 181 (37.8)
  Mean (SD) 67.2 (13.4) 68.5 (12.7) 67.3 (11.7) 65.6 (11.6) < 0.001
  Median 69 70 68 66
Sex (%)
  Male 100,682 (61.5) 68,577 (66.5) 926 (70.9) 346 (72.2) < 0.001
  Female 63,109 (38.5) 34,566 (33.5) 380 (29.1) 133 (27.8)
Race (%)
  White 118,825 (72.5) 74,681 (72.4) 951 (72.8) 371 (77.5) < 0.001
  Black 19,550 (11.9) 11,583 (11.2) 236 (18.1) 61 (12.7)
  Other 25,416 (15.5) 16,879 (16.4) 119 (9.1) 47 (9.8)
Detection Stage (%)
  Localized 41,461 (25.3) 22,366 (21.7) 227 (17.4) 59 (12.3) < 0.001
  Regional 45,864 (28.0) 32,103 (31.1) 337 (25.8) 186 (38.8)
  Distant 58,576 (35.8) 38,774 (37.6) 541 (41.4) 206 (43.0)
  Unstaged 17,890 (10.9) 9,900 (9.6) 201 (15.4) 28 (5.8)
Grade Differentiation (%)
  Well 9,547 (5.8) 4,779 (4.6) 64 (4.9) 3 (0.6) < 0.001
  Moderate 30,480 (18.6) 25,698 (24.9) 330 (25.3) 63 (13.2)
  Poor 75,552 (46.1) 49,344 (47.8) 542 (41.5) 306 (63.9)
  Unknown 48,212 (29.4) 23,322 (22.6) 370 (28.3) 107 (22.3)
Surgery (%)
  Yes 81,339 (49.7) 50,124 (48.6) 342 (26.2) 263 (54.9) < 0.001
  No 82,452 (50.3) 53,019 (51.4) 964 (73.8) 216 (45.1)
Chemotherapy (%)
  Yes 63,961 (39.1) 42,283 (41.0) 575 (44.0) 244 (50.9) < 0.001
  No 99,830 (60.9) 60,860 (59.0) 731 (56.0) 235 (49.1)
Radiotherapy (%)
  Yes 31,035 (18.9) 22,608 (21.9) 505 (38.7) 160 (33.4) < 0.001
  No 132,756 (81.1) 80,535 (78.1) 801 (61.3) 319 (66.6)
Incidence Rate (95% CI) -
  All 73.7 (73.3 - 74.1) 43.6 (43.3 - 43.9) 0.57 (0.54 - 0.61) 0.19 (0.17 - 0.21)
  Male 99.9 (99.2 - 100.7) 65.2 (64.7 - 65.8) 0.90 (0.83 - 0.97) 0.29 (0.26 - 0.34)
  Female 53.1 (52.6 - 53.5) 26.4 (26.1 - 26.7) 0.30 (0.27 - 0.34) 0.10 (0.08 - 0.12)
CSS (95% CI) -
  1-year 56.8 (56.5 - 57.1) 53.3 (52.9 - 53.7) 38.2 (34.6 - 41.8) 44.3 (38.2 - 50.3)
  2-year 43.1 (42.7 - 43.4) 37.7 (37.3 - 38.1) 24.9 (21.7 - 28.2) 23.7 (18.6 - 29.2)
  5-year 32.5 (32.1 - 32.8) 26.0 (25.7 - 26.4) 18.4 (15.4 - 21.6) 16.9 (12.5 - 22.0)
  10-year 28.5 (28.2 - 28.8) 22.3 (21.9 - 22.7) 17.1 (14.1 - 20.4) 14.0 (9.7 - 19.0)
  Median (Months) 16.6 13.7 7.7 10.3
RS (95% CI) -
  1-year 53.5 (53.2 - 53.8) 49.9 (49.5 - 50.3) 35.3 (31.9 - 38.7) 41.4 (35.5 - 47.2)
  2-year 39.1 (38.8 - 39.4) 33.9 (33.5 - 34.3) 22.8 (19.8 - 25.9) 21.7 (16.9 - 26.8)
  5-year 26.5 (26.2 - 26.8) 20.7 (20.3 - 21.0) 14.6 (12.0 - 17.5) 14.7 (10.7 - 19.4)
  10-year 19.0 (18.8 - 19.3) 13.9 (13.6 - 14.3) 10.9 (8.5 - 13.6) 9.5 (6.1 - 13.9)
  Median (Months) 14.0 12.0 6.8 9.4

P < 0.05 for all comparisons between adenocarcinoma, squamous cell carcinoma and adenosquamous cell carcinoma comparisons. Incidence rates were expressed per 100,000. CSS: cause-specific survival; RS: relative survival; CI: confidence interval; SD: standard deviation.